PARIS, FRANCE: Onxeo S.A., a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR) in oncology, announced the formation of a new Scientific Advisory Committee of leading scientific and clinical experts in the fields of DDR, resistance to treatment and more globally, drug development in oncology.
The Committee will advise and guide the Company as it advances its proprietary platform of compounds in the DDR field and develops innovative therapeutics that address unmet medical needs and improve the management of cancer patients.
“We feel excited and privileged to be able to work with this eminent group of renowned thought leaders in oncology,” said Judith Greciet, Chief Executive Officer of Onxeo.
“Their scientific advice and clinical expertise will be extremely useful to determine the best development strategies for AsiDNA and to leverage its unique properties. Furthermore, their support will be particularly valuable to design new and differentiated candidates from our platON platform in order to enrich our pipeline of decoy agonists.”
Gilbert Chu, MD, PhD, Professor of Medicine (Oncology) and Biochemistry at the Stanford Medical School, commented: “The decoy-agonist technology that Onxeo is developing is a very promising new approach which consists in hijacking the DNA damage response for cancer treatment. AsiDNA presents appealing and original anti-tumoral properties which could lead to new therapeutic strategies, particularly for cancers with a high unmet medical need.”
Gilles Favre, PharmD, Medical Biologist, PhD, Director of CRCT (Toulouse Research Center in Cancerology), concluded: “Onxeo is addressing a major unmet need in cancer treatment that is prevention or reversal of tumor drug resistance. The early work performed by our team on combining AsiDNA™ with targeted therapies has shown promising results and I look forward to help advance these developments with my distinguished colleagues.”
Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.
Onxeo SA
0.66 EUR −0.0020 (0.30%)
28 May, 5:35 pm GMT+2 · Disclaimer
EPA: ALONX
Leave a Reply